biostudies-literatureUnknown11(5)Picchianti Diamanti AAbbVie<h4>Introduction</h4>Clinical remission is the main target in the management of patients with rheumatoid arthritis (RA). However, several authors found synovitis in patients with RA in clinical remission at ultrasonography (US). Upadacitinib is a selective Janus kinase 1 inhibitor that achieved significantly higher remission rates than adalimumab and abatacept in patients with RA. Here we present the 24-week data of the UPAdacitinib Rheumatoid Arthritis REmission UltraSonography (UPARAREMUS) study.<h4>Methods</h4>This is a longitudinal multicenter observational study, enrolling bio-naïve and bio-inadequate responder patients affected by RA. The primary endpoint was the proportion of patients achieving both clinical and US remission at week 24. The proportion of patients achieving clinical Rheumatology and therapy1347-1361https://www.ebi.ac.uk/biostudies/studies/S-EPMC11422397biostudies-literatureClinical and Ultrasonographic Remission in Bio-naive and Bio-failure Patients with Rheumatoid Arthritis at 24 Weeks of Upadacitinib Treatment: The UPARAREMUS Real-Life Study.PMC11422397Chimenti MSDe Lorenzo CSebastiani GPaci VPerricone CD'Antonio ALagana BScirocco CCattaruzza MSCanzoni MFrediani BLuchetti MMZabotti AGiovannini IIagnocco APicchianti Diamanti ASesti GFelice GMDi Rosa RBaldi CCrepaldi GSalemi SfalseClinical and Ultrasonographic Remission in Bio-naive and Bio-failure Patients with Rheumatoid Arthritis at 24 Weeks of Upadacitinib Treatment: The UPARAREMUS Real-Life Study.<h4>Introduction</h4>Clinical remission is the main target in the management of patients with rheumatoid arthritis (RA). However, several authors found synovitis in patients with RA in clinical remission at ultrasonography (US). Upadacitinib is a selective Janus kinase 1 inhibitor that achieved significantly higher remission rates than adalimumab and abatacept in patients with RA. Here we present the 24-week data of the UPAdacitinib Rheumatoid Arthritis REmission UltraSonography (UPARAREMUS) study.<h4>Methods</h4>This is a longitudinal multicenter observational study, enrolling bio-naïve and bio-inadequate responder patients affected by RA. The primary endpoint was the proportion of patients achieving both clinical and US remission at week 24. The proportion of patients achieving clinical 2024-01-01T00:00:00Z2024 Oct2025-04-22T21:43:04.835Z2025-04-22T21:43:04.835ZS-EPMC114223973917774510.1007/s40744-024-00712-y